Sugi Predict

Sugi Predict / Targets / TRIM24

TRIM24

Transcription intermediary factor 1-alpha · O15164 · TRIM24 on Sugi Atlas →

36,797 patent compounds predicted against TRIM24, 25,664 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Iguratimod Iguratimod (SCHEMBL26326) 0.36 8/20
SCHEMBL327222 SCHEMBL327222 0.50 3/20
SCHEMBL93023 SCHEMBL93023 0.46 3/20
SCHEMBL265640 SCHEMBL265640 0.45 3/20
SCHEMBL146118 SCHEMBL146118 0.43 3/20
SCHEMBL111707 SCHEMBL111707 1.00 2/20
SCHEMBL112034 SCHEMBL112034 1.00 2/20
SCHEMBL190509 SCHEMBL190509 1.00 2/20
SCHEMBL268555 SCHEMBL268555 1.00 2/20
Salicyladehyde Salicyladehyde (SCHEMBL50021) 0.82 2/20
Salicyladehyde Salicyladehyde (SCHEMBL183269) 0.75 2/20
Cyclohexanone Cyclohexanone (SCHEMBL74298) 0.69 2/20
SCHEMBL110906 SCHEMBL110906 0.65 2/20
SCHEMBL110907 SCHEMBL110907 0.65 2/20
SCHEMBL272370 SCHEMBL272370 0.65 2/20
SCHEMBL272371 SCHEMBL272371 0.65 2/20
SCHEMBL284379 SCHEMBL284379 0.65 2/20
Cyclohexanone Cyclohexanone (SCHEMBL295059) 0.65 2/20
Ortho-Phthalaldehyde Ortho-Phthalaldehyde (SCHEMBL33393) 0.63 2/20
SCHEMBL113066 SCHEMBL113066 0.61 2/20

Clinical trials — most relevant to TRIM24 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
RNA Cloning and Visualization in Human Atherosclerosis nanCOMPLETED
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee nanCOMPLETED
Novel Intervention to Influence Muscle Plasticity in Veterans nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes nanRECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Functioning of Elder Muscle; Understanding Recovery nanCOMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development nanCOMPLETED
Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TRIM24 binder may also engage these)

ProteinNameSimilarity
Q64127 — 1.000 Q64127 →
Q99PP7 — 0.998 Q99PP7 →
TRIM33 E3 ubiquitin-protein ligase TRIM33 0.998 landscape →
Q56R14 — 0.996 Q56R14 →
Q6E2N3 — 0.992 Q6E2N3 →
Q09YG9 — 0.989 Q09YG9 →
Q9H694 — 0.989 Q9H694 →
Q5IS89 — 0.988 Q5IS89 →
Q5XJV7 — 0.988 Q5XJV7 →
KAT2B Histone acetyltransferase KAT2B 0.988 landscape →
Q09YJ3 — 0.988 Q09YJ3 →
O70546 — 0.988 O70546 →
Q9XSB5 — 0.988 Q9XSB5 →
Q9TU15 — 0.987 Q9TU15 →
Q6EE22 — 0.987 Q6EE22 →
Q07E15 — 0.987 Q07E15 →
P63008 — 0.987 P63008 →
P63006 — 0.987 P63006 →
Q9XSW2 — 0.987 Q9XSW2 →
Q5U4T7 — 0.987 Q5U4T7 →
Q5U2Z7 — 0.987 Q5U2Z7 →
Q2IBF8 — 0.987 Q2IBF8 →
Q2IBE6 — 0.986 Q2IBE6 →
O88907 — 0.986 O88907 →
Q8TEW0 — 0.986 Q8TEW0 →
Q4V7W5 — 0.986 Q4V7W5 →
Q5IS44 — 0.986 Q5IS44 →
P48742 — 0.986 P48742 →
Q96KQ4 — 0.986 Q96KQ4 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.986 landscape →